Prelude Therapeutics Incorporated (PRLD)
Develops targeted cancer drugs that attack specific genetic mutations in tumors.
$4.42+0.14%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+433.2%
The outlook
PRLD trades at $4.42, sitting well above both its 50- and 200-day moving averages, with analyst consensus strongly bullish at 1.3 on the buy scale. The stock sits roughly three-quarters of the way through its 52-week range, and the average analyst price target sits around 81% above the current price.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 3 analysts
Price trendAbove its 50- & 200-day averages
52-week range74% of the way from its 52-week low to high
Price targetAvg target +81% vs current price
Analyst price target
~12-month · 3 analysts$8.00average target+81.2% vs now
Now $4.42
Low $6.00High $10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$351.6M
52-wk high
$5.69
52-wk low
$0.75
50-day avg
$4.30
200-day avg
$3.05
Trailing P/E
—